Leukemia research · 2012
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
Оценочное исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yhim Ho-Young, Lee Na-Ri, Song Eun-Kee, Yim Chang-Yeol, Jeon So Yeon, Shin Seunghwan, Kim Jeong-A, Kim Hee Sun, Cho Eun Hae, Kwak Jae-Yong
Аннотация
The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5 months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.
Предметные рубрики MeSH
AdultAgedAntineoplastic AgentsBenzamidesFeasibility StudiesFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedMolecular Diagnostic TechniquesNeoadjuvant TherapyPiperazinesPyrimidinesRemission InductionRetrospective StudiesWithholding Treatment